Journal: Journal of Clinical Medicine

Article Title: Oral Intake of the Commercial Probiotic Blend Synbio ® for the Management of Vaginal Dysbiosis

doi: 10.3390/jcm12010027

Figure Lengend Snippet: Microbial count and ANOVA significance of the vaginal discharge samples collected at baseline (T0), 15 days after the start of treatment (T1), and 7 days after the end of oral SYNBIO ® administration (T2). Data are shown as mean and standard deviation.

Article Snippet: The commercial probiotic blend SYNBIO ® is a combination of Lacticaseibacillus rhamnosus IMC 501 ® and Lacticaseibacillus paracasei IMC 502 ® strains formulated by SYNBIOTEC Srl (Camerino, Italy).

Techniques:

Journal: Gut Microbes

Article Title: Randomized controlled trial demonstrates response to a probiotic intervention for metabolic syndrome that may correspond to diet

doi: 10.1080/19490976.2023.2178794

Figure Lengend Snippet: Study overview. (a) CONSORT flow diagram for enrollment, allocation, follow-up, and analysis. (b) Metabolic syndrome guidelines as defined by the International Diabetes Foundation (IDF). (c) Heat map depicting the study inclusion criteria met by participants (rows) along with medication use. Those that only satisfied 2 criteria are indicated by an asterisk. Yellow line separates placebo from probiotic arm. HDL = high density lipoprotein; BP = blood pressure (d) Stool and blood samples along with participant food logs were collected over an 18-week period for microbiome and immune system measurements.

Article Snippet: The probiotic supplement contained a proprietary blend of three probiotic strains ( Limosilactobacillus reuteri NCIMB 30242, Lactiplantibacillus plantarum UALp-05TM, and Bifidobacterium animalis subsp. lactis B420TM), which were verified through sequencing ( Fig. S1A ), and at least 20 billion colony forming units per capsule.

Techniques:

Journal: Gut Microbes

Article Title: Randomized controlled trial demonstrates response to a probiotic intervention for metabolic syndrome that may correspond to diet

doi: 10.1080/19490976.2023.2178794

Figure Lengend Snippet: MetSyn parameters did not improve in the probiotic arm, but participants cluster into responder and non-responder groups. (A) MetSyn parameters and (B) alanine aminotransferase (ALT), insulin, and LDL cholesterol at baseline (“B”, week 0) and end of intervention (“W10”, week 10) for probiotic (n=21; participants that had at least 3 elevated parameters and thus met the definition of metabolic syndrome) and placebo arms (n=13). (C) Change from baseline average (weeks -4, -2, 0) to end of intervention (weeks 8, 10) for each participant in placebo, probiotic responder (R), or probiotic non-responder (NR) groups. All probiotic participants (n=26) plotted including those with only 2 elevated parameters (‪ indicates participants that only satisfied 2 criteria for MetSyn). Each row is a participant and is hierarchically clustered by parameters shown. § indicates significant difference between average baseline and end of intervention within the probiotic responders (paired t-test < 0.05). ‡ indicates significant difference between average percent fold change between probiotic responders and placebo (unpaired t-test < 0.05). † indicates significant difference between average baseline and end of intervention within the probiotic non-responders (paired t-test < 0.05). # indicates significant difference between average percent fold change between probiotic non-responders and placebo (unpaired t-test <0.05). (D) Principal coordinate analysis of Euclidean distances for % change in inflammatory marker from baseline (week -3) to end of intervention (week 10) for all participants. Circles denote 50% confidence level for a multivariate t-distribution. (E) Change in serum homovanillic acid levels from baseline (week -3) to end of intervention (week 10) for placebo, probiotic non-responders (NR), and responders (R) (unpaired t-test, post-hoc p-value = 0.004).

Article Snippet: The probiotic supplement contained a proprietary blend of three probiotic strains ( Limosilactobacillus reuteri NCIMB 30242, Lactiplantibacillus plantarum UALp-05TM, and Bifidobacterium animalis subsp. lactis B420TM), which were verified through sequencing ( Fig. S1A ), and at least 20 billion colony forming units per capsule.

Techniques: Marker

Journal: Gut Microbes

Article Title: Randomized controlled trial demonstrates response to a probiotic intervention for metabolic syndrome that may correspond to diet

doi: 10.1080/19490976.2023.2178794

Figure Lengend Snippet: Probiotic responders exhibit distinct microbiome profiles. (a) Within-participant Bray-Curtis distance of amplicon sequenced variants (ASVs) relative to the first baseline time point (week 0) plotted over time by arm (unpaired t-test p values for each time point between arms are shown) (n=13 placebo; n=26 probiotic). (b) Within-participant Bray-Curtis distance, week 0 vs. week 10 by arm and response group (n=14 R; n=12 NR). (c) Bray-Curtis distance of the ASVs for the placebo, probiotic responders and non-responders at the end of the intervention (week 10) are plotted. Circles denote 50% confidence level for a multivariate t-distribution. ASVs driving the separation between groups are depicted as green circles, collapsed to average loading across genus. Size of green circles indicate prevalence (% present across all samples at week 10).

Article Snippet: The probiotic supplement contained a proprietary blend of three probiotic strains ( Limosilactobacillus reuteri NCIMB 30242, Lactiplantibacillus plantarum UALp-05TM, and Bifidobacterium animalis subsp. lactis B420TM), which were verified through sequencing ( Fig. S1A ), and at least 20 billion colony forming units per capsule.

Techniques: Amplification

Journal: Gut Microbes

Article Title: Randomized controlled trial demonstrates response to a probiotic intervention for metabolic syndrome that may correspond to diet

doi: 10.1080/19490976.2023.2178794

Figure Lengend Snippet: Dietary intake differentiating probiotic responders and non-responders. (A) Nutrients that differ between probiotic responders (n=14) and non-responders (n=12) across the entire study (weeks -4 through 14), normalized by median body weight (kg) (siggenes, FDR < 0.05, q-value < 0.1). Scaled nutrient intake is the mean intake value subtracted from each value and divided by the standard deviation. The line within the box plot represents the median value. (B) Scaled average food group intake (weeks 0 and 10) in which the mean value is subtracted from each value and divided by the standard deviation normalized for median body weight between responders and non-responders (sweets; unpaired t-test, p-value = 0.010). The line within the box plot represents the median value.

Article Snippet: The probiotic supplement contained a proprietary blend of three probiotic strains ( Limosilactobacillus reuteri NCIMB 30242, Lactiplantibacillus plantarum UALp-05TM, and Bifidobacterium animalis subsp. lactis B420TM), which were verified through sequencing ( Fig. S1A ), and at least 20 billion colony forming units per capsule.

Techniques: Standard Deviation

Journal: Journal of Perinatology

Article Title: Contemporary use of prophylactic probiotics in NICUs in the United States: a survey update

doi: 10.1038/s41372-024-01952-0

Figure Lengend Snippet: Characterization of prophylactic probiotic use in US NICUs.

Article Snippet: Further, an FDA warning to Abbott Laboratories on October 24, 2023 led to discontinued sales of Similac ® Probiotic Tri-Blend.

Techniques: Probiotics

Journal: Journal of Perinatology

Article Title: Contemporary use of prophylactic probiotics in NICUs in the United States: a survey update

doi: 10.1038/s41372-024-01952-0

Figure Lengend Snippet: Characterization of opinions towards AAP probiotic statement and an FDA-approved probiotic formulation.

Article Snippet: Further, an FDA warning to Abbott Laboratories on October 24, 2023 led to discontinued sales of Similac ® Probiotic Tri-Blend.

Techniques: Formulation, Probiotics

Journal: Microbiome Research Reports

Article Title: Probiotics, prebiotics, synbiotics and other microbiome-based innovative therapeutics to mitigate obesity and enhance longevity via the gut-brain axis

doi: 10.20517/mrr.2024.05

Figure Lengend Snippet: Recent double-blinded randomized controlled clinical trials on probiotic therapies for obesity and aging

Article Snippet: A microencapsulated probiotic blend ( L. rhamnosus NCIMB 6375, L. plantarum NCIMB 8826 and L. fermentum NCIMB 5221) was also studied for its effects on HFD-induced MetS hamsters and resulted in favorable alterations to the gut microbiota through decreasing the F/B ratio [ ] .

Techniques: Clinical Proteomics, Reflux